New-Onset Inflammatory Bowel Diseases Among IL-17 inhibitors-Treated Patients: Results From The Case-Control MISSIL Study.
Jean-Guillaume LetarouillyThao PhamAdeline PieracheÉmilie AcquacaldaBeatrice BannevilleSébastien BarbarotPauline BaudartÉlodie BauerPascal ClaudepierreArnaud ConstantinEmmanuelle DernisRenaud FeltenPhilippe GaudinCéline GirardBruno GombertPhilippe GoupilleXavier GuennocIsabelle Henry-DesaillyDenis JullienElena KarimovaSylvain LanotLoïc Le DantecTristan PascartLaurianne PlastarasNathalie SultanXavier TruchetStephane VarinDaniel WendlingLouise GaboriauDelphine Staumont-SalléLaurent Peyrin-BirouletRene-Marc FlipoPublished in: Rheumatology (Oxford, England) (2021)
The incidence of new IBD was low and decreased from 2016 to 2019. The outcome was favourable in 24 out of 31 patients, but two patients died.